Gerard Bastian, PhD

home / authors / gerard-bastian-phd

Articles

Impact of UFT on Tumoral TS and DPD Levels in Colorectal Cancer

Gerard Bastian, PhD;Jean-franÇois Seitz, MD;Vincent Moutardier, MD;Jean Robert Delperro, MD;Pierre Fargeot, MD;Jean Fraisse, MD;Patricia Formento, PhD;Michel Chazard, MD;Nicole Renée, PhD;Gerard Milano, PhD

October 1st 2000

This was an open lable, pilot translational clinical pharmacology study of a brief (7 day) course of UFT, 300 mg/m²/day, in combination with leucovorin, 90 mg/day, in six patients with newly diagnosed advanced colorectal cancer.

European Experience With Irinotecan Plus Fluorouracil/Folinic Acid or Mitomycin

David Khayat, MD, PhD;Marian Gil-delgado, MD, PhD;Eric-charles Antoine, MD;David Coeffic, MD;A. Benhammouda, MD;J. P. Grapin, MD;Gerard Bastian, PhD

August 1st 1998

Tremendous progress has been made in the medical treatment of advanced colorectal cancer during the past 2 to 3 years, due to the availability of several new drugs. Of these new agents, irinotecan (CPT-11 [Camptosar]) seems